Neuromedin U has a novel anorexigenic effect independent of the leptin signaling pathway.
about
Identification of neuromedin S and its possible role in the mammalian circadian oscillator systemSensitivity of the hypothalamic paraventricular nucleus to the locomotor-activating effects of neuromedin U in obesityNeuromedin S and UThe antiobesity effects of centrally administered neuromedin U and neuromedin S are mediated predominantly by the neuromedin U receptor 2 (NMUR2)Emerging pharmacology and physiology of neuromedin U and the structurally related peptide neuromedin SNeuromedin U receptor 2-deficient mice display differential responses in sensory perception, stress, and feeding.Neuromedin U and its putative Drosophila homolog huginPeptide neuromodulation in invertebrate model systemsA neuromedin U receptor acts with the sensory system to modulate food type-dependent effects on C. elegans lifespanNovel role of the anorexigenic peptide neuromedin U in the control of LH secretion and its regulation by gonadal hormones and photoperiodLeptin resistance contributes to obesity and hypertension in mouse models of Bardet-Biedl syndromeThe Anorexigenic Peptide Neuromedin U (NMU) Attenuates Amphetamine-Induced Locomotor Stimulation, Accumbal Dopamine Release and Expression of Conditioned Place Preference in MiceThe neuropeptide neuromedin U promotes inflammation by direct activation of mast cellsNeuromedin U is regulated by the metastasis suppressor RhoGDI2 and is a novel promoter of tumor formation, lung metastasis and cancer cachexia.Suppression of insulin production and secretion by a decretin hormone.Negative regulation of neuromedin U mRNA expression in the rat pars tuberalis by melatonin.The c-Myb target gene neuromedin U functions as a novel cofactor during the early stages of erythropoiesisChanges in brain tissue and behavior patterns induced by single short-term fasting in mice.New genetic loci link adipose and insulin biology to body fat distribution.Hypothalamic inflammation: a double-edged sword to nutritional diseases.Identification of G Protein-Coupled Receptors (GPCRs) in Primary Cilia and Their Possible Involvement in Body Weight Control.Small lipidated anti-obesity compounds derived from neuromedin U.Medical sequencing at the extremes of human body mass.Peptides and their potential role in the treatment of diabetes and obesity.Peri-implantation lethality in mice carrying megabase-scale deletion on 5qc3.3 is caused by Exoc1 null mutationThe neuropeptide neuromedin U promotes autoantibody-mediated arthritis.Epidermal Neuromedin U Attenuates IgE-Mediated Allergic Skin InflammationThe role of neuromedin U in adiposity regulation. Haplotype analysis in European children from the IDEFICS CohortNeuropeptides controlling energy balance: orexins and neuromedins.Regulation of bone remodeling by the central and peripheral nervous systemCLP1 links tRNA metabolism to progressive motor-neuron loss.Neuroregulation of nonexercise activity thermogenesis and obesity resistance.Neuromedin U receptor 2 knockdown in the paraventricular nucleus modifies behavioral responses to obesogenic high-fat food and leads to increased body weight.Regulation of motivation for food by neuromedin U in the paraventricular nucleus and the dorsal raphe nucleus.Adaptive capacity to bacterial diet modulates aging in C. elegans.Roles of leptin in bone metabolism and bone diseases.New cancer cachexia rat model generated by implantation of a peritoneal dissemination-derived human stomach cancer cell line.Development of a neuromedin U-human serum albumin conjugate as a long-acting candidate for the treatment of obesity and diabetes. Comparison with the PEGylated peptide.Inactivation of the von Hippel-Lindau tumour suppressor gene induces Neuromedin U expression in renal cancer cells.Similar changes of hypothalamic feeding-regulating peptides mRNAs and plasma leptin levels in PTHrP-, LIF-secreting tumors-induced cachectic rats and adjuvant arthritic rats.
P2860
Q24557456-755D6618-E632-4ECD-9912-A2C6EB715D7CQ24644836-F4DEE679-52DF-4D3C-9C15-5D9381A5A906Q24656108-DC747B3F-17C6-47E2-9A65-52F899A1A320Q24656123-B3E11774-18D1-41E4-8306-BA2AED4877FCQ24656469-679905EE-5C7E-46B9-B3C0-3B613393B8D8Q24672413-B9AABCA6-592D-4B6B-86DC-2641DB1D67A9Q25257583-C7DC4EB6-71B0-4238-B2F9-07D9F4B43206Q26864612-51BE28CE-19F3-4761-A4E9-BB4A52F4BEAAQ27324458-00073E00-D7EA-46B9-9D03-42D1FA51D3B5Q28242546-5E3C4FFF-24B2-43A3-BE83-178908199F53Q28511291-B0B95B27-E5B5-4A61-A2FF-98004E6E0E2BQ28551732-31C3559F-3C51-4332-9708-2D14FF6EE298Q28755876-F625FC02-373B-4B4C-9E76-81DAA2DB30B5Q30441149-2B6D73E1-981E-4D39-91A1-ACECFA9CF3E9Q34461248-41811AA2-9381-4EB8-B1F0-CEA9FE721D14Q34812443-6A263F43-BAFB-447A-906F-46D8BCEE4E97Q35030940-BBEA146A-3852-4123-8DB1-7BD15079D37EQ35041611-1D7B5D18-044C-4730-AAFE-A10D660B6467Q35114362-E3280829-C3E6-4C35-B880-60F1B6EA8880Q35318592-744F0BAD-BE25-4082-BE4A-507019CC5EBEQ35656487-91C811C8-380B-4BC5-9B1F-B7F84F97FDA2Q35708420-4ED67DA1-47E5-48F5-B109-7A5B5BE584BBQ35752505-D8CECC4B-6931-49C3-BC5E-CE99AA669E8DQ35760298-DD1C154E-DB0F-47B0-AED8-7C09113E6DACQ36034930-46E971E2-CE31-4A5E-8507-2CB6DAF4D683Q36085002-B67F628A-56DB-40B4-B35B-F50165B45AF3Q36087071-F8031ECF-5D0D-41BF-9C96-3AE86E67EBA4Q36290147-6402A375-D5DB-40D8-8662-A2A0C1A85F50Q36531499-39846F19-8926-46DA-A995-310061EBC2EAQ36724983-A8C8F1B8-72BF-4183-8E3B-F6E88099FC5AQ36907351-A0483AD9-0499-42D3-A72B-0113BB8B38F4Q37045418-B11D8BFC-094F-4D33-BA45-39494489F9E5Q37502658-3735BD4E-C167-45C8-8D38-24BC03990772Q37553137-95970171-D85D-4EBA-B477-5593BF91B071Q37691717-489BB3DB-5112-4456-98B6-F6BD716098A4Q38380562-49DFB70E-79CB-42E3-89E8-BD3C08E81CAFQ39042463-2648E713-91FC-4AC4-B716-FA46CD156011Q39063782-DF8954E1-96B9-44FD-B539-2D821DBADE0AQ39500622-643404F0-0AF1-43F1-B640-DADB7F263950Q39684347-3E994CFD-AD8D-471A-ADCC-58271F13603E
P2860
Neuromedin U has a novel anorexigenic effect independent of the leptin signaling pathway.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Neuromedin U has a novel anorexigenic effect independent of the leptin signaling pathway.
@en
Neuromedin U has a novel anorexigenic effect independent of the leptin signaling pathway.
@nl
type
label
Neuromedin U has a novel anorexigenic effect independent of the leptin signaling pathway.
@en
Neuromedin U has a novel anorexigenic effect independent of the leptin signaling pathway.
@nl
prefLabel
Neuromedin U has a novel anorexigenic effect independent of the leptin signaling pathway.
@en
Neuromedin U has a novel anorexigenic effect independent of the leptin signaling pathway.
@nl
P2093
P2860
P50
P356
P1433
P1476
Neuromedin U has a novel anorexigenic effect independent of the leptin signaling pathway
@en
P2093
Hiroaki Fujihara
Hironobu Yoshimatsu
Hiroshi Hosoda
Hitoshi Teranishi
Kenji Kangawa
Mamoru Kurokawa
Masayasu Kojima
Mikiyasu Shirai
Noboru Murakami
Nobuhiro Fukushima
P2860
P2888
P304
P356
10.1038/NM1106
P407
P577
2004-09-26T00:00:00Z